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Abstract
Background: Decisions concerning drug safety and eﬃcacy are generally based on pivotal evidence provided by
clinical trials. Unfortunately, ﬁnding the relevant clinical trials is diﬃcult and their results are only available in
text-based reports. Systematic reviews aim to provide a comprehensive overview of the evidence in a speciﬁc area,
but may not provide the data required for decision making.
Methods: We review and analyze the existing information systems and standards for aggregate level clinical trials
information from the perspective of systematic review and evidence-based decision making.
Results: The technology currently used has major shortcomings, which cause deﬁciencies in the transfer, traceability
and availability of clinical trials information. Speciﬁcally, data available to decision makers is insuﬃciently structured,
and consequently the decisions cannot be properly traced back to the underlying evidence. Regulatory submission,
trial publication, trial registration, and systematic review produce unstructured datasets that are insuﬃcient for
supporting evidence-based decision making.
Conclusions: The current situation is a hindrance to policy decision makers as it prevents fully transparent decision
making and the development of more advanced decision support systems. Addressing the identiﬁed deﬁciencies
would enable more eﬃcient, informed, and transparent evidence-based medical decision making.
Background
Motivation
Health care policy decision makers such as drug regula-
tory authorities, reimbursement policy makers and guide-
line committees routinely evaluate the eﬃcacy and safety
of medicines, as well as other factors such as costs. Clin-
ical trials provide the pivotal evidence for drug eﬃcacy
and safety. The ability to eﬃciently identify and make
use of the results of existing clinical trials is critical to
evidence-based policy decision making.
Until recently, journal publications were the only gener-
ally available source of trial designs and results. Thus, sys-
tematically reviewing themedical literature for the clinical
trials that address a speciﬁc topic is of central importance
*Correspondence: g.h.m.van.valkenhoef@rug.nl
1Department of Epidemiology, University of Groningen, University Medical
Center Groningen, Groningen, The Netherlands
2Faculty of Economics and Business, University of Groningen, Groningen, The
Netherlands
Full list of author information is available at the end of the article
to evidence-based health care policy [1,2]. This provides
decision makers with a coherent overview of the cur-
rent evidence, and also helps to set the agenda for future
clinical research [3,4]. However, systematic reviewing is
currently not feasible for most decision makers, because it
is time consuming and expensive.
Therefore, most decision makers will have to rely on
published systematic reviews. However, this is problem-
atic because the review may not match the needs of the
decision maker. Thus, even when a relevant systematic
review is available, there may be a need to go back to the
underlying trial data, especially for quantitative decision
modeling. It may additionally be necessary to update or
extend the review, or to combine several of them. Doing so
also requires access to the underlying trial data, but these
are not commonly reported. This is a serious limitation to
the eﬃciency of both evidence-based decisionmaking and
systematic reviewing.
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Thus, the quality of health care policy could be
improved if systematic reviews could be performed for
whatever decision is currently at hand, ideally even on
demand. This would require enormous improvements
to the manner in which clinical trials evidence is made
available. Although eﬀorts to standardize the information
systems for the management and regulatory submission
of clinical trials have been successful [5-7], this has not
so far resulted in similar improvements in the dissemina-
tion of clinical trial evidence. A comprehensive overview
of the various information systems that store and pro-
cess clinical trials information could identify the gaps in
information transfer that limit the eﬃciency of system-
atic reviews and consequently health care policy decision
making.
Systematic review
The need to identify and summarize the evidence for deci-
sion makers is evident from the sheer scale of the avail-
able information: PubMed alone indexes nearly 20 million
publications from over 5,500 journals, and this is only a
selected subset of the biomedical literature [3]. Systematic
review addresses this need and consists of three steps: lit-
erature screening, data extraction, and reporting. In the
ﬁrst step, literature databases are searched, yielding a set
of potentially relevant publications. These are screened
for suitability, which results in them being included in, or
excluded from, the review. Because literature searches are
often inaccurate, thousands of publications may need to
be screened. Moreover, to ensure comprehensiveness and
avoid bias, multiple databases have to be searched [8] and
multiple publications of a single trial have to be identi-
ﬁed as such. Once the relevant trials have been identiﬁed
and the corresponding reports retrieved, the data have
to be extracted from the reports. Finally, the collected
data are summarized and combined (e.g. using meta-
analysis), and reported in a journal article or a technical
report. Typically only this ﬁnal product is made avail-
able, even though making the results of the screening step
and the extracted data available would greatly enhance
the eﬃciency of future systematic reviews and decision
making. Thus, to assess the eﬃciency of clinical trials
results dissemination, systematic review should not be
ignored.
The diﬃculty of performing a systematic review also
impacts the quality of systematic reviews themselves: it
leads to reviews that focus on a single treatment or a pair
of treatments. Consequently, for one particular therapeu-
tic indication many competing reviews may be available,
that each provide only a small part of the overall picture
[9]. This has led to ‘overviews of reviews’ or ‘umbrella
reviews’ summarizing the results of several existing
reviews [10]. Umbrella reviews generallymerely repeat the
pooled summaries of treatment eﬀects from the original
reviews, but it has been argued that they may lead to
misleading and inconsistent conclusions [9]. An approach
based on the individual studies is therefore preferable but
labor-intensive if the data are not available in a structured
format.
Scope and objectives
The aim of this paper is to identify opportunities to
enhance the eﬃciency of systematic review and evidence-
based decision making, supported by a broad and useful
overview of the current state of the art in the transfer
and availability of clinical trial evidence. To these ends,
we provide a critical overview of existing systems and
standards that support the dissemination of clinical trial
results.
Because publicly available clinical trial results are nearly
always aggregated (at the population level) rather than
reported per patient, and because most decision mak-
ers base their decisions on such data, we limit the scope
of this paper to systems and standards for the aggregate
level.
Methods
We included academic publications and websites of man-
ufacturers or standardization bodies that describe infor-
mation systems or standards that deal with the transfer
and availability of aggregate-level results of clinical tri-
als. We also considered review articles and peer-reviewed
position papers related to such information systems.
We identiﬁed relevant publications through key word
searches using Google, Google Scholar, ISI Web of Sci-
ence and PubMed (last searched May 2011). We also
screened the reference lists of included publications. In
addition, through our participation in the Escher project
of the Dutch Top Institute Pharma (TI Pharma), we were
able to engage in discussions with many experts from
the pharmaceutical industry, regulatory authorities, and
academia.
Publications (both peer-reviewed articles and web pages
published by companies or standardization bodies) were
screened for eligibility using titles and abstracts (if appli-
cable). Potentially relevant publications were read in full. If
a peer-reviewed article and a web page conveyed (nearly)
identical information, only the peer-reviewed work was
included.Moreover, web pages were excluded if the source
was not considered authoritative for the subject matter.
Included publications were summarized using keywords,
and especially important sections were highlighted for
later reference. For each system and standard we collected
the context in which it is used, its purpose, its deﬁning
features, the types of data it handles and/or produces, its
connection to other systems or standards, and expected
future developments.
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Results
In this section, we present the identiﬁed systems grouped
according to the processes they support. These are pub-
lication in the scientiﬁc literature, trial registration, sys-
tematic review, and regulatory assessment. Figure 1 shows
how these processes relate to each other, to the oper-
ation of the trial itself, and to policy decision making.
Subsequently, standards and data models relevant to the
dissemination of aggregate level results of clinical trials are
discussed.
Scientiﬁc literature
Pharmaceutical industry and other investigators may
choose to summarize selected results of clinical tri-
als in manuscripts submitted to peer-reviewed scien-
tiﬁc journals. A clinical trial may result in any number
of publications, from none to dozens. Unfortunately,
such publications frequently lack suﬃcient information to
allow the reader to judge whether the trial was rigorously
conducted. The CONSORT statement [11,12] aims to
improve the situation by providing guidance on the proper
reporting of clinical trials. Nevertheless, trial reporting is
often still inadequate [13] and selective outcome reporting
is common [14].
Reporting clinical trial results in text-based articles
rather than properly structured data sets makes compu-
tational processing of the results practically impossible
[15]. Moreover, although peer review is essential to guar-
antee the quality of such articles, publication in scientiﬁc
journals scatters the results throughout the scientiﬁc lit-
erature. The problem of identifying and accessing clinical
trial publications is addressed by abstract databases and
search engines, most notably PubMed (http://pubmed.
com/), backed by the MEDLINE database, and EMBASE
(http://embase.com/), which maintains its own database;
see Table 1 for their coverage. Both databases label
abstracts using controlled vocabularies, allowing the
restriction of searches to clinical trials, controlled clini-
cal trials, or systematic reviews of clinical trials. However,
not all abstracts might be labeled, which is why systematic
reviewers often broaden their search beyond these cat-
egories. PubMed’s Clinical Queries (http://pubmed.com/
clinical) provide optimized search strategies that have
been empirically validated for this use [16]. It might be
useful in these cases to annotate which abstracts do not
belong to reports of clinical trials. Research is ongoing
to improve the accuracy of search results through text
processing of abstracts [17] and to aid the screening pro-
cess by ranking the search results [18]. The Cochrane
CENTRAL database of trial publications [19], kept up-
to-date by the non-commercial Cochrane Collaboration
(http://www.cochrane.org/), provides links to publica-
tions known to describe randomized controlled trials.
It is quarterly updated from MEDLINE, EMBASE, and
databases of specialized Cochrane groups [20] Records
that are identiﬁed as clinical trials are reported back to
MEDLINE.
When clinical trial results were only published in scien-
tiﬁc journals, the decision whether to publish the results
was completely left to the investigator, which led to
incomplete trial reporting and publication bias [21]. For
example, over half of the clinical trials that supported suc-
cessful new drug applications made to the FDA had still
not been published 5 years after the medicines’ market
approval [22]. This is a serious problem that can lead to
incorrect conclusions from a systematic review.
Trial registration
As early as 1986 the registration of trials in advance was
proposed as a solution to publication bias [23]. The trial
bank concept proposes to take the registration of trials
even further by recording not only the existence of a trial,
but also the study protocol (in advance) and the results
(after completion) in a “machine readable” way [15,24].
For trial banks to be successful, all trials must be entered
in a way that conforms to a single machine-readable data
model [24,25]. The Global Trial Bank project was set up
in 2005 to create a practically usable trial bank [26], but in
2008 it was put on hold due to lack of funding [27].
The FDA Modernization Act of 1997 made the US the
ﬁrst country to make trial registration a legal require-
ment. To implement this legislation, the ClinicalTrials.gov
registry was launched in February 2000 [28]. The ini-
tial installment focused on providing a record of trials
Figure 1 An overview of the processes dealing with clinical trials information and how they relate to each other.
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Table 1 Coverage of abstract databases PubMed and EMBASE, and the Cochrane Library
all records since 2000 source
PubMed/MEDLINE (1 Jan 2011)
PubMed records 19,569,568 6,628,156 (1)
Identiﬁed clinical trial 457,378 171,025 (1)
Identiﬁed randomized controlled trial 293,963 156,496 (1)
Identiﬁed meta-analysis 25,723 21,146 (1)
Indexed journals 5,543 1,287 (2) 17 May 2011
EMBASE (17 May 2011)
EMBASE records ∼ 24 M (3)
EMBASE journals ≥ 7,500 (3)
Cochrane library (17 May 2011)
Clinical trials (CENTRAL) 645,086 286,418 (4) issue 2 of 4, Apr 2011
Cochrane reviews 4,621 4,621 (4) issue 5 of 12, May 2011
Other reviews 14,602 12,683 (4) issue 2 of 4, Apr 2011
All reviews (Cochrane + Other) 19,223 17,304






for enabling patient recruitment and investigator account-
ability. In 2004, both the World Health Organization
(WHO) and the International Committee ofMedical Jour-
nal Editors (ICMJE) released statements in support of the
prospective registration of clinical trials. This policy has
been widely adopted and now assures that the existence
of most recent trials is known [29]. Subsequently, vari-
ous organizations, including the WHO, have called for
a full disclosure of the trial protocol (including amend-
ments) and results [30-36]. In the US, recent legislation
[37] has required protocol registration since December
2007, basic results reporting since September 2008, and
Adverse Drug Events (ADEs) reporting since Septem-
ber 2009 [38]. Other governments with policies requiring
prospective registration include the EU, India, Argentina,
Brasil, Israel and South Africa [39].
To register a trial in ClinicalTrials.gov [40], researchers
enter summary protocol information [41] when their
studies are initiated, and subsequently create the results
section [42] when the data collection for at least one
primary outcome measure is complete. The ClinicalTri-
als.gov staﬀ will review the results data after their submis-
sion. The data are reported in a structured tabular format
and some meta-data, such as units of measurement or the
use of standard vocabularies, can also be provided. Lim-
ited support for reporting statistical analyses is oﬀered;
these analyses are tied to speciﬁc results tables. Study pro-
tocols have long been available in XML format, and the
retrieval of results in XML format was added in December
2011 [43].
Other countries have set up their own registries. Since
2004, the European Medicines Agency (EMA) has estab-
lished clinical trial registration in accordance with the
EU Directive 2001/20/EC through the EudraCT system.
EudraCT was opened to the public only recently as the
EU Clinical Trials Register, on 22 March 2011 [44], and
the records are being released in a staggered fashion. Cur-
rently 17,102 [45] of over 28,150 registered trials [46]
are available. Another international registry is the Cur-
rent Controlled Trials Ltd.’s ISRCTN registry, which has
been in operation since 1998 [47]. It provides a semi-
structured textual representation of the trial protocol, but
no results. A number of countries have open national reg-
istries that generally record information in a way similar to
ISRCTN. All of these registries are less sophisticated than
ClinicalTrials.gov.
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In order to unify trial registration world-wide, theWHO
International Clinical Trials Registry Platform (ICTRP)
was established following the Ministerial Summit on
Health Research in November 2004. The goal of the
ICTRP is to create “a network of international clinical
trial registries to ensure a single point of access and
the unambiguous identiﬁcation of trials” [48]. This net-
work of trial registries, the WHO Registry Network, was
formally launched in 2007. In March 2012, 14 primary
registries were listed on the ICTRP website (see Table 2).
The ICTRP also provides a search portal that collects and
indexes some basic information on trials from most of the
primary registries and attempts to group trials that are
registered in more than one registry in the search results.
The search portal provides a textual description of the
trial design as well as a link to the primary registry. Table 2
gives an overview of the WHO primary registries and
ClinicalTrials.gov, with the number of included studies
and whether or not they are indexed by the search portal.
ClinicalTrials.gov is by far the largest registry, containing
more than 7 times the number of trials available in the
second largest registry (EU Clinical Trials Register), and
69% of all trials in the registries (not taking duplicates into
account). Moreover, ClinicalTrials.gov is the only registry
that registers results. In January 2010 it had published
the results of 1,156 studies, which had increased to 5,436
studies by March 2012.
Although a decentralized system of federated registries
(both national and multi-national) seems cumbersome
and may cause duplicate registration, there are important
reasons why this method is to be preferred to a centralized
approach [49]: national registries, for example, are in the
position to ensure complete registration in their region of
inﬂuence and are perfectly aligned with the local political
situation. As long as the diﬀerent registries are suﬃciently
interoperable, an overarching organization such as the
ICTRP can aggregate their databases.
The increased transparency enabled by trial registration
oﬀers new opportunities for evidence-based medicine
and will likely lead to an increase in the number of
systematic reviews that are undertaken [50]. However,
the current registries contain only text-based or semi-
structured information and lack a common coding sys-
tem, for example for labeling interventions. The amount
of protocol information registered is often insuﬃcient to
judge the validity of reported results and the problem of
identifying all relevant studies has not yet been solved
[29]. In addition, the publicly available information may
be incomplete or even “largely incomprehensible” [38].
The call for federated, open access, mandatory results
databases continues [32-36], and it is likely that the trend
toward open and complete registration of results will
continue.
Systematic review
The process of systematic review produces data andmeta-
data that is potentially useful for future reviewers and
decision makers (see Background). The following assesses
whether the existing information systems enable the dis-
semination of this information.
Table 2 ClinicalTrials.gov and the 14WHO primary registries, with the number of registered trials per 19March 2012
(‘studies’), whether the register is indexed by theWHO search portal (‘indexed’) and whether the registry also enables
results publication (‘results’)
Register Studies Indexed Results
ClinicalTrials.gov (United States) 122,758 yes yes (5,436)
European Union Clinical Trials Register 17,102 no no
ISRCTN register (international) 10,465 yes no
Japan Primary Registries Network 8,329 yes no
Australian New Zealand Clinical Trials Registry 6,369 yes no
The Netherlands National Trial Register 3,187 yes no
Clinical Trials Registry - India 2,499 yes no
Iranian Registry of Clinical Trials 2,449 yes no
Chinese Clinical Trial Register 2,004 yes no
German Clinical Trials Register 831 yes no
Cuban Public Registry of Clinical Trials 392 yes no
South Korea Clinical Research Information Service 379 yes no
Brazilian Clinical Trials Registry 131 no no
Pan African Clinical Trial Registry 97 yes no
Sri Lanka Clinical Trials Registry 71 yes no
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The Cochrane Collaboration provides several databases
to support reviewers. Besides the CENTRAL database
of clinical trials (see Section Scientiﬁc literature) the
most relevant ones are the Cochrane Database of Sys-
tematic Reviews, in which Cochrane reviews are pub-
lished [51], and the DARE database of other reviews.
Table 1 provides statistics regarding the scope of the
library. In contrast to the traditional journal publica-
tions of systematic reviews, which usually provide data
in tables or ﬁgures, the Cochrane Reviews incorpo-
rate descriptions and results of the original studies.
However, the published dataset has many data ele-
ments removed and the use of the data is restricted by
license.
There are several software programs to aid in systematic
review and meta-analysis, such as Comprehensive Meta-
Analysis, MetaWin, MetaStat and MetaAnalyst. More-
over, many general-purpose statistical programs, such as
SPSS Statistics, SAS Statistics, Stata, and R, have meta-
analysis functionality. In general, dedicated meta-analysis
software will provide easier data entry and management,
while statistical programs will oﬀer more powerful tools
for analysis. The Cochrane Collaboration also provides
the Review Manager software for performing systematic
reviews (http://ims.cochrane.org/revman). Review Man-
ager is unique in that it provides not only data analysis
and management features, but includes functionality to
write the full systematic review report. Indeed, the Review
Manager ﬁle itself is submitted to the Cochrane library
for review and eventual publication. Unfortunately, all of
these systems lack suﬃcient meta-data to enable auto-
mated processing.
Finally, published systematic reviews are usually pre-
sented in a textual format without the underlying
dataset, making it diﬃcult to perform additional anal-
yses that may be required for decision making. Thus,
the inclusion of data on a new trial or new com-
pound, as would be required for regulatory decision
making, is also impossible. In conclusion, systematic
review currently represents a missed opportunity to intro-
duce additional structure to the available clinical trials
information.
Regulatory assessment
After a pharmaceutical company develops a drug, it com-
piles the evidence collected from the discovery and devel-
opment processes into a dossier that is submitted to the
regulators who decide upon its market authorization. Sub-
missions to the EMA and the national medicines boards
in Europe are mainly text-based, containing aggregate-
level results of clinical trials based on the applicant’s
statistical analysis. The Food and Drug Administration
(FDA) requests the submission of patient-level data, which
is unlikely to become publicly available and as such is
out of scope for this paper. The dossier forms the basis
on which regulators assess the beneﬁt-risk proﬁle of a
new drug. Although the clinical trial results are pivotal
in this assessment, the decision is only indirectly based
on them, as the decision making process is based on
informal discussion between experts. While the deci-
sion may still be of high quality, this informal framework
does not allow pharmaceutical companies or patients to
discern how diﬀerent pieces of the evidence weigh in
on it.
The EMA publishes the European Public Assessment
Reports (EPARs) of all centrally approved or refused
medicines on its website. Note that this does not include
all applications submitted to the EMA, as they can be
withdrawn before a decision is reached [52]. The EPAR
contains information on all trials, but is completely tex-
tual without a semantic structure. Moreover, its infor-
mation is directly derived from the submission by the
applicant, while there is no standardization concern-
ing what information should be provided, or in which
format. Trials submitted to the EMA are required to
be registered in EudraCT and will thus also be made
known to the public through the EU Clinical Trials
Register.
Standards and data models
A common standard of how clinical trials are performed
and how their results are presented would make the pro-
cess of systematic review more reliable and less laborous
[15]. Some progress has been made by ClinicalTrials.gov,
which currently registers and displays aggregate results.
To do so, ClinicalTrials.gov has developed their own
model, the Data Element Deﬁnitions (DED) [41,42]. This
model allows the reporting of aggregated outcome data
and statistical analyses to some extent, but the infor-
mation cannot be processed automatically because most
ﬁelds are free text. This also means that ﬁnding all trials
that are relevant to a speciﬁc patient condition is inac-
curate, and thus requires overly broad search terms [53].
This lack of standardization and interoperability among
registries and other databases should be addressed in the
near future.
Several projects aim to enable general purpose re-use
of clinical trials information, e.g. for cross-study analyses.
We identiﬁed three such projects. The ﬁrst is the Biomed-
ical Research Integrated Domain Group (BRIDG) project,
a collaboration between the Clinical Data Interchange
Standards Consortium (CDISC), Health Level 7 (HL7), the
National Cancer Institute (NCI) and the FDA that aims
to bring together the common elements of their various
standards into a complete data model for clinical trials
[54]. The BRIDG model is implementation-independent
in the sense that it speciﬁes the problem domain, not a
speciﬁc solution. For example, unlike some other CDISC
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standards it does not specify the format in which to
submit data to the FDA. BRIDG is subdivided between
the protocol representation, study conduct, adverse event
and regulatory perspectives. Unfortunately, a data analy-
sis perspective is currently missing as there is no adequate
standard for the modelling of statistical analyses. In short,
the BRIDG model is accurate as regards the management
of a single clinical trial, but not as regards cross-study
analysis [55]. For example, the study population and eligi-
bility criteria, outcomes and the measures used to assess
outcomes do not have a suﬃciently deep semantic struc-
ture.
To enable cross-study analyses and eﬃciently ﬁnd-
ing relevant trials, the Human Studies Database (HSDB)
project aims to share fully machine understandable rep-
resentations of study design information between institu-
tions [55]. HSDB is developing the Ontology of Clinical
Research (OCRe), which deﬁnes the concepts that should
be accessible across the individual institutions’ databases.
At the time of writing, OCRe included a study design
representation derived from BRIDG [55], a study design
typology [56], the ERGO formal machine readable repre-
sentation of eligibility criteria [53], and a model of study
outcomes that separates the phenomena of interest from
the variables that encode them [55]. While OCRe is a
promising eﬀort, its representation of study design is far
from comprehensive, and it completely lacks a model for
trial results.
Finally, the Ontology Based eXtensible conceptual
model (OBX) is another ontology for representing clinical
trials [57,58]. Its aim is to make the results of immunol-
ogy studies available for data re-use and re-analysis. The
OBX also incorporates study design representation ideas
from BRIDG and the ClinicalTrials.gov DED [57].While it
appears successful in developing a broadly applicable data
model for biomedical studies, and also allows the inclu-
sion of trial results, it would appear that OBX suﬀers from
similar shortcomings as regards the depth of modelling as
BRIDG does.
All of the discussed models rely on an external cod-
ing system for their clinical content. Such coding systems,
known as controlled terminologies of clinical terms, are
an important ﬁrst step in the application of information
technology to medicine [59]. There are many controlled
terminologies for medicine, often developed for speciﬁc
applications, but unfortunately there is as yet no stan-
dardization of which ones should be used, and there is
no accurate mapping between them [60,61]. For example,
in clinical research the Medical Dictionary for Regula-
tory Activities (MedDRA) is used to code ADEs, while the
healthcare area prefers the Systematized Nomenclature of
Medicine, Clinical Terms (SNOMEDCT) dictionary. This
hinders the interoperability of the various information
systems being used.
Discussion
Having reviewed the information systems and standards
dealing with the information from clinical trials, we
will now summarize their deﬁciencies concerning the
integration of clinical trials information from diﬀerent
resources, discuss how the status quo could be improved
and identify directions for future research.
Identiﬁed deﬁciencies
Systems and standards oriented towards the management
of single studies are relatively mature, but this is not the
case for cross-study analysis. There are no known large,
successful, and publicly available data warehouses, nor
any standards that would enable cross-study analyses of
aggregate level results. Considerable eﬀort is required to
harmonize the current clinical research standards. Impor-
tant areas that require standardization are the represen-
tation of statistical analyses and aggregate results, as well
as complex semantic structures such as patient eligibil-
ity criteria. None of the general purpose data models
being developed are yet in widespread use, and from the
perspective of capturing the designs and results of clin-
ical trials in a reusable way, none of them are close to
completion.
Although much eﬀort is spent to publish the results of
clinical trials, the current systems do not facilitate opti-
mal use of the information. The journals and abstract
databases that publish the trial results do not preserve
the results’ structure and thus require manual data extrac-
tion. Moreover, relevant articles are hard to identify and
the retrieval of all available studies cannot be guaran-
teed. Public registries are meant to improve the eﬃ-
ciency and reliability of the identiﬁcation of relevant
studies, but the available data is not suﬃciently struc-
tured to realize this. Moreover, the systems that currently
deal with clinical trials results are not interlinked nor
do they use interoperable standards. In short, there is
not yet a comprehensive system of structured machine-
understandable databases that contains descriptions of
the design, execution, and summary-level results of indi-
vidual trials. This situation hinders systematic review
and makes cross-study analyses and data-mining pro-
hibitively diﬃcult. Thus, current infrastructure is focused
on text-based reports of single studies, whereas eﬃcient
evidence-based medicine requires the automated integra-
tion of multiple clinical trials from diﬀerent information
resources.
Moreover, while systematic review collects and
appraises the available evidence that is relevant to a
certain question, the results are published in an unstruc-
tured format. This makes it hard to use the underlying
data to inform evidence-based decisions, to verify
the analyses, to update the review or to perform a
combined analysis of several reviews for an umbrella
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review. The eﬀort spent on literature screening and
data extraction does not result in availability of this
information for future reviewers, leading to duplication
of eﬀort.
Therefore, the current systems are unnecessarily bur-
densome and do not suﬃciently facilitate reuse of the
information. Figure 2 visualizes the current results dis-
semination process. Due to these shortcomings, deci-
sions are not explicitly linked to the underlying evidence,
leading to a lack of transparency, traceability, and repro-
ducibility that is harmful for all stakeholders.
Importantly, the perceived lack of transparency in
regulatory decision making may erode public trust in
drug regulation and the pharmaceutical industry. More
explicit quantitative decision models would enable a
more transparent and reproducible regulatory process,
as well as a clearer communication of the requirements
to the industry. However, for most real-world decisions
it is currently too expensive to include all the evi-
dence. This diﬃculty of accessing existing data is not
only relevant to regulators and the industry, but also to
reimbursement organizations, prescribing physicians and
patients.
Proposed future situation
Now, we consider how these deﬁciencies might be
addressed. Let us assume for a moment that a compre-
hensive machine-understandable standard were available
for the design and aggregate level results of clinical tri-
als. Then, it would be better for those submitting the data
if both regulators and registries used this format, rather
than a number of disparate formats. In addition, journal
publications could easily be supplemented with data in
this format.
Availability of a standard alone, however, is not enough
to enable eﬃcient access to the evidence. The data sets
also need to be collected and made available in such a way
that relevant clinical trials are easily identiﬁed. For this
a collaborative (federated) system of databases should be
established to capture all clinical trials data. Some of the
stakeholders (e.g. regulators and registries) may require
that data be submitted to a database that they control
so that they can ensure the integrity of the data. This is
ﬁne as long as (1) the databases are interoperable and
enable access to the information in the same format, (2)
there is a single point of access through which the dif-
ferent databases can be identiﬁed and located, and (3)
duplicate entries can be easily identiﬁed. It seems more
likely for such a combination of databases to emerge
from the current registries than a single centralized
system.
A comprehensive record of clinical trials in a machine-
understandable format would make systematic review
and consequently evidence-based decision making much
more eﬃcient. Decisions could then ﬁnally be explicitly
linked to the underlying data (traceability). In addi-
tion, this could also enable a new generation of deci-
sion support systems for health care policy decision
makers. The proposed future situation is visualized in
Figure 3.
However, a suitable general-purpose data model is not
likely to become available in the near future. Further,
the usefulness of any data model should be demon-
strated to the industry and other stakeholders before
Figure 2 In the current system of clinical trials results dissemination, data are collected in three separate systems (not including the
organization that performs the trial).
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Figure 3 The alternative solution for clinical trials results dissemination proposed in this paper: harmonization of the diﬀerent systems to
create a uniﬁed platform for evidence-based decision making. Regulatory assessment has been merged into general policy decision making.
putting it into practice. We argue that the require-
ments for a general purpose data model for cross-
study analysis and decision making are not suﬃciently
well known at the moment. Therefore, analysis tools
and decision support systems that ensure data extrac-
tion done for the analysis can be shared with other
researchers should be developed ﬁrst, to illuminate these
requirements.
Research directions
In order to attain the desired future system for
aggregate-level clinical trial results dissemination, we
identify concrete research directions for medical infor-
matics, decision making and statistics researchers.
Progress on each of these topics can be made in
parallel.
• Computer-supported decision models for policy
decision making based on clinical trials – to enable a
direct and explicit link between the decision and the
supporting evidence in drug regulation,
reimbursement policy and guideline formulation
• Development of a platform to share structured
systematic review data sets
• Discovery or creation of incentives for systematic
reviewers to share the results of literature screening
and data extraction
• Identiﬁcation of the core data elements and modeling
that are needed to increase the accuracy of literature
searches
• Automated tagging and data extraction to facilitate
transition to more structured data sets
• Development of search tools to integrate querying of
abstract databases and registries
• Development of methods to identify duplicate trial
publications and registrations
• Development of a comprehensive data model for
clinical trials and their aggregate level results
Limitations
As with any review paper, there is a risk that rele-
vant publications have not been identiﬁed, either because
the search terms were not broad enough, or because
relevant studies were not identiﬁed as such based
on their title and abstract. We acknowledge that the
broad scope of this particular review increases that
risk.
The nature of the collected information necessitates a
qualitative synthesis, and the identiﬁed deﬁciencies are at
least partially subjective. The future that we propose is
based on the premise that a standard for aggregate clinical
trial data will become available. Unfortunately, it is unclear
how and when this could be realized. Finally, the list of
proposed research directions is sure to be incomplete,
and we hope the present paper will ignite discussions on
this topic.
Conclusions
We reviewed the existing systems and standards deal-
ing with aggregate level results of clinical trials. The
transfer of evidence to scientiﬁc journals, public reg-
istries, and regulators is a largely ad hoc and text-based
aﬀair. In part, this is because there are currently no
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data standards that enable cross-study analyses. We have
argued that the lack of a standardized, federated system
for results dissemination leads to gaps in the transfer
and availability of evidence to the relevant decision mak-
ers. As long as such a system does not exist, systematic
review will remain an incredibly ineﬃcient ad-hoc pro-
cess, and evidence-based decision making will remain
unnecessarily diﬃcult. We believe that these diﬃculties
lead to a lack of transparency in health care policy deci-
sion making, which threatens public trust in the decision
makers.
In the future, results registries and regulatory systems
should be harmonized and federated to create a system of
databases that forms the core of a more automated and
eﬃcient process of systematic review and evidence-based
decision making. In addition, systematic reviews are cur-
rently a missed opportunity to introduce additional struc-
ture to the domain of clinical trials information, which
should be addressed by more complete dissemination of
their results. Although this vision is still far from real-
ized, current trends seem to support this direction. Future
work should not only focus on developing the ‘ideal’ data
model for all of clinical research (justly called a monu-
mental task) but start by creating useful tools to support
decision makers and systematic reviewers. Availability of
such tools will lead to increased demand for an acces-
sible evidence base and to a better understanding of its
requirements.
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